Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call
April 26 2013 - 9:00AM
Marketwired
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it
will report first quarter 2013 financial results on May 2, 2013.
The Company will host a conference call that day at 5:00 p.m.
Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-888-771-4371 from the United States or
1-847-585-4405 internationally approximately 10 minutes before the
start of the call. The passcode is 34774024.
A replay will be available through May 16, 2013 at
1-888-843-7419 from the United States and +1-630-652-3042
internationally. The passcode is 34774024.
About Corcept Therapeutics
Incorporated
Corcept is a pharmaceutical company engaged in the discovery,
development and commercialization of drugs for the treatment of
severe metabolic and psychiatric disorders. In April 2012, Corcept
began offering its first product, Korlym® (mifepristone) 300 mg
Tablets, a first-generation GR-II antagonist, as a once-daily oral
treatment of hyperglycemia secondary to endogenous Cushing's
syndrome in adult patients who have type 2 diabetes mellitus or
glucose intolerance and have failed surgery or are not candidates
for surgery.
The company has a phase 3 trial underway for mifepristone for
treatment of the psychotic features of psychotic depression and a
portfolio of selective GR-II antagonists that block the effects of
cortisol but not progesterone. It owns extensive intellectual
property covering the use of GR-II antagonists, including
mifepristone, in the treatment of a wide variety of metabolic and
psychiatric disorders. It also holds composition of matter patents
for its selective GR-II antagonists.
CONTACT: Charles Robb Chief Financial Officer Corcept
Therapeutics 650-688-8783 Email Contact www.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024